These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15147415)

  • 1. Pharmacogenomics and transplantation: where are we?
    Frassetto LA; Benet LZ
    Am J Transplant; 2004 Jun; 4(6):843. PubMed ID: 15147415
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.
    MacPhee IA; Fredericks S; Tai T; Syrris P; Carter ND; Johnston A; Goldberg L; Holt DW
    Am J Transplant; 2004 Jun; 4(6):914-9. PubMed ID: 15147425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus pharmacogenetics: bringing the laboratory into the clinic.
    McLaren A
    Transplantation; 2003 Dec; 76(11):1541-2. PubMed ID: 14705621
    [No Abstract]   [Full Text] [Related]  

  • 4. Future of the pharmacogenomics of calcineurin inhibitors in renal transplant patients.
    Zhu H; Ge W
    Pharmacogenomics; 2011 Nov; 12(11):1505-8. PubMed ID: 22044409
    [No Abstract]   [Full Text] [Related]  

  • 5. A genetic test for immunosuppressant dose selection?
    Thummel KE
    Pharmacogenetics; 2004 Mar; 14(3):145-6. PubMed ID: 15167701
    [No Abstract]   [Full Text] [Related]  

  • 6. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
    Prytuła A; van Gelder T
    Pediatr Nephrol; 2019 Jan; 34(1):31-43. PubMed ID: 29479631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
    Coto E; Tavira B
    Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians.
    Macphee IA; Fredericks S; Mohamed M; Moreton M; Carter ND; Johnston A; Goldberg L; Holt DW
    Transplantation; 2005 Feb; 79(4):499-502. PubMed ID: 15729180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.
    Jacobson PA; Oetting WS; Brearley AM; Leduc R; Guan W; Schladt D; Matas AJ; Lamba V; Julian BA; Mannon RB; Israni A;
    Transplantation; 2011 Feb; 91(3):300-8. PubMed ID: 21206424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence.
    Vicari-Christensen M; Repper S; Basile S; Young D
    Prog Transplant; 2009 Sep; 19(3):277-84. PubMed ID: 19813492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
    Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
    Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort.
    Bolley R; Zülke C; Kammerl M; Fischereder M; Krämer BK
    Transplantation; 2002 Mar; 73(6):1009. PubMed ID: 11923712
    [No Abstract]   [Full Text] [Related]  

  • 15. Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.
    Leroy S; Isapof A; Fargue S; Fakhoury M; Bensman A; Deschênes G; Jacqz-Aigrain E; Ulinski T
    Pediatr Nephrol; 2010 May; 25(5):965-9. PubMed ID: 20091056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
    Wang J
    Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.
    Lancia P; Adam de Beaumais T; Elie V; Garaix F; Fila M; Nobili F; Ranchin B; Testevuide P; Ulinski T; Zhao W; Deschênes G; Jacqz-Aigrain E
    Pediatr Nephrol; 2018 Jun; 33(6):1045-1055. PubMed ID: 29399716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
    Kniepeiss D; Renner W; Trummer O; Wagner D; Wasler A; Khoschsorur GA; Truschnig-Wilders M; Tscheliessnigg KH
    Clin Transplant; 2011; 25(1):146-50. PubMed ID: 20041908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics and lung transplantation: clinical implications.
    Burckart GJ; Hutchinson IV; Zeevi A
    Pharmacogenomics J; 2006; 6(5):301-10. PubMed ID: 16520825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.